Mundipharma has announced the extension of its strategic partnership with Kolon Life Science to market Invossa-K in Saudi Arabia and United Arab Emirates. Invossa-K is a treatment for osteoarthritis pain with long-term efficacy. The agreement builds on the existing co-promotion agreement between the two companies in Korea signed in April 2017.

First approved by the Korean Ministry of Food and Drug Safety (MFDS) in 2017, the treatment has been hailed as the world's first cell-mediated gene therapy for osteoarthritis. Invossa-K is an intra-articular injection that is non-surgical treatment option, demonstrating sustained pain reduction and functional improvement of articular joint for two years following a single injection in a US phase II clinical trial and one year in a Korean phase III clinical trial.

Under the terms of the partnership, Mundipharma will be responsible for the marketing and distribution of Invossa-K to medical professionals and hospitals in Saudi Arabia and United Arab Emirates.